Investors & Industry

Collaborating for Cures

We have an entire team dedicated to the convergence of science and business — to advance our goal of revolutionizing cancer treatment.

We’re always searching for connections to help cure cancer. Join us.

The Business Development & Strategy Team at Fred Hutch has a stellar track record of finding partners who share our drive to innovate, collaborate and accelerate the development of high-impact technologies and therapies. The result has been dozens of licensing agreements, strategic partnerships, spinouts and startups, including such high-profile launches as Juno Therapeutics, Adaptive Biotechnologies, Nohla Therapeutics and Faraday Pharmaceuticals.

385+

Active Inventions

We seek opportunities to license our inventions and other intellectual property to encourage product development and spur new businesses.

View Our Available Technologies

60K

Square Feet of Shared Facilities

Fred Hutch investigators have shared access to facilities and resources where they can design experiments, analyze data and seek research breakthroughs.

Our Shared Resources

38

Companies Founded on Our Science

To translate our discoveries to the clinic, we seek partners who share our drive to innovate, collaborate and save lives.

View Our Collaborations

250K+

Square Feet of Lab Space

Our state-of-the-art laboratories keep our researchers’ work moving forward as quickly as possible.

Our Facilities and Infrastructure

Featured Technology

Colon Cancer Biomarkers

The Lampe Lab at Fred Hutch has identified and validated a five-protein panel for early detection of colon cancer and adenoma. Two independent studies have confirmed this biomarker panel. Colon cancer is the third-leading cause of cancer-related deaths in the U.S.; about 150,000 new cases are diagnosed each year. Early detection dramatically increases the odds of survival.

Available Technologies

Dr. Stan Riddell speaking during and IIRC retreat.

Our three integrated research centers are launchpads for novel immunotherapies, vaccines, and technologies that have strong commercial potential. Bringing together top talent from multiple disciplines, they enable the efficient translation of scientific insights into real-world solutions.

Stephen MacFarlane runs the electron microscope in the Cellular Imaging Department.

Our investigators and research partners have access to a suite of cutting-edge services and programs that help them get to discoveries faster. They include specialized facilities and equipment, integrated research centers, powerful data science infrastructure, and computational advisory services.

Featured Partnership

Juno Therapeutics

The pioneering immunotherapy company Juno Therapeutics was founded in 2013 as a partnership between Fred Hutch, Memorial Sloan-Kettering Cancer Research Center and Seattle Children’s Research Institute, licensing cutting-edge research from all three institutions. It launched with $120 million in private investment funding, making it one of the largest biotech startups in history. Juno initially targeted blood cancers but has expanded its focus to include some solid-tumor cancers, such as colorectal cancer and certain sarcomas, in further partnership with Fred Hutch investigators.

Spinouts & Startups

Lab technician Tessa Dignum takes notes on a computer in the Hadland Lab.

Data-Intensive Bioscience

We provide state-of-the-art data infrastructure and data science support for our investigators in areas such as data mining, machine learning, mobile app development and bioinformatics.

Learn More